What is Nomic?
Nomic Bio operates at the intersection of advanced DNA nanotechnology and proteomics, providing a seamless protein profiling service that significantly reduces turnaround times for researchers. By utilizing its nELISA platform, the company enables high-throughput analysis capable of processing over 10,000 samples per week. This technological edge offers pharmaceutical and biotech entities a cost-efficient, flexible solution for comprehensive proteomic data, which is essential for modern drug discovery and precision medicine initiatives. The company's ability to deliver rapid, high-fidelity insights positions it as a critical infrastructure provider for the next generation of life science research.
How much funding has Nomic raised?
Nomic has raised a total of $59M across 2 funding rounds:
Series A
$17M
Series B
$42M
Series A (2021): $17M with participation from Lux Capital, Casdin Capital, and SR One
Series B (2024): $42M led by Amplitude Ventures, Lux Capital, Real Ventures, and Avant Bio
Key Investors in Nomic
Amplitude Ventures
Amplitude Venture Capital deploys a growth model focused on building Canadian companies with world-class management teams, applying an evidence-based approach to investing in leading precision medicine firms.
Lux Capital
Lux Capital is a New York-based venture capital firm that invests in early-stage and growth-stage companies at the intersection of science and technology, with a specific focus on biotechnology and advanced materials.
Real Ventures
Real Ventures supports mission-driven entrepreneurs by providing stage-specific guidance and community resources to help innovative tech companies achieve global success.
What's next for Nomic?
With the successful closure of this Series B round, Nomic is poised to scale its infrastructure to meet the surging demand for high-throughput proteomic data. The strategic focus will likely shift toward enhancing the scalability of its nELISA platform and deepening its integration within the pharmaceutical R&D pipeline. By utilizing this capital, the company aims to solidify its role as a foundational partner for life science vanguards, potentially expanding its multiplexing capabilities and further optimizing its machine learning-driven analytical workflows. As the firm matures, the emphasis will remain on maintaining its competitive advantage in turnaround speed and cost-efficiency, ensuring that it remains the preferred partner for organizations seeking to accelerate their therapeutic development cycles.
See full Nomic company page
